Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6547685 | 0.84 | TDP1 (0.47) | MEN1KMT2ATDP1ALDH1A1TSHR | |
| SCHEMBL4585193 | 0.77 | KMT2A (0.47) | MEN1KMT2AALDH1A1TSHRRXRA | |
| SCHEMBL4585877 | 0.74 | KMT2A (0.43) | MEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL2828217 | 0.74 | MEN1 (0.43) | MEN1KMT2ATDP1ALDH1A1CA2 | |
| SCHEMBL4587294 | 0.73 | MEN1 (0.43) | MEN1KMT2AGRM2 | |
| SCHEMBL11703047 | 0.72 | MEN1 (0.63) | MEN1KMT2ATDP1ALDH1A1TSHR | |
| SCHEMBL10601315 | 0.72 | GABRA1 (0.47) | TDP1ALDH1A1TSHRATMCA2 | |
| SCHEMBL10599697 | 0.71 | MEN1 (0.37) | MEN1KMT2ATDP1ALDH1A1ATM | |
| SCHEMBL186055 | 0.70 | MEN1 (0.67) | MEN1KMT2ATDP1ALDH1A1ATM | |
| SCHEMBL713859 | 0.70 | ALDH1A1 (0.48) | MEN1KMT2ATDP1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785001-B2 | Organic electroluminescent devices | MERCK PATENT GMBH (DE) | 2014-07-22 | — | — | US | disclosed |
| US-8304095-B2 | Organic electroluminescent devices | MERCK PATENT GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-20080297037-A1 | Organic Electroluminescent Devices | MERCK PATENT GMBH (DE) | 2008-12-04 | — | — | US | disclosed |
| US-20080272693-A1 | Organic Electroluminescent Devices | MERCK PATENT GMBH (DE) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080272693-A1 | Organic Electroluminescent Devices | EML4, MT-ND4L, EPCAM | MEN1 3327/4885KMT2A 1866/4885TDP1 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.